Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | BHMT | Q93088 | 1/20 | 0.48 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.46 |
| ▸ | GSR | P00390 | 2/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16577956 | 0.87 | SLC7A5 (0.64) | SLC7A5BHMTBHMT2SLC1A3SLC1A2 | |
| SCHEMBL27399381 | 0.84 | GGT1 (0.54) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL59989 | 0.81 | BHMT (0.55) | SLC7A5BHMTBHMT2SLC1A3SLC1A2 | |
| SCHEMBL17039475 | 0.81 | BHMT (0.55) | SLC7A5BHMTBHMT2SLC1A3SLC1A2 | |
| SCHEMBL13269874 | 0.81 | BHMT (0.55) | SLC7A5BHMTBHMT2SLC1A3SLC1A2 | |
| SCHEMBL1895927 | 0.81 | BHMT (0.55) | SLC7A5BHMTBHMT2SLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL3219774 | 0.79 | BHMT (0.53) | SLC7A5BHMTBHMT2SLC1A3SLC1A2 | |
| SCHEMBL2420176 | 0.79 | — | — | |
| SCHEMBL60414 | 0.79 | — | — | |
| SCHEMBL17039474 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20220033518-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | AMBRX,INC. (US) | 2022-02-03 | — | — | US | disclosed |
| EP-3170821-B1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX INC (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20210277056-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-10954270-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3470413-A2 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | Ambrx, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10208123-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-3170821-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | Ambrx, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150080559-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives | AMBRX, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| WO-2012166560-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012166559-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2007079130-A2 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | SLC7A5 264/4885BHMT 2844/4885BHMT2 2360/4885 |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | CD74, CD63, CD47 | SLC7A5 264/4885BHMT 2844/4885BHMT2 2360/4885 |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AR, PSMA1, NR2E3 | SLC7A5 1727/4885BHMT 1769/4885BHMT2 1811/4885 |
| US-10208123-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | SLC7A5 264/4885BHMT 2844/4885BHMT2 2360/4885 |
| US-20210277056-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | DDOST, DAD1, PTMS | SLC7A5 127/4885BHMT 91/4885BHMT2 54/4885 |
| US-10954270-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | DDOST, DAD1, PTMS | SLC7A5 127/4885BHMT 91/4885BHMT2 54/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | SLC7A5 221/4885BHMT 2765/4885BHMT2 2151/4885 |
| US-20220033518-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | KLK3, PTMS, DDOST | SLC7A5 545/4885BHMT 53/4885BHMT2 74/4885 |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | KLK3, PTMS, DDOST | SLC7A5 545/4885BHMT 53/4885BHMT2 74/4885 |
| US-20150080559-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives | DDOST, DAD1, PTMS | SLC7A5 132/4885BHMT 96/4885BHMT2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.